Inomagen Therapeutics, Inc.
Chicago, IL
- UEI
- G361MCGUDEE5
- CAGE
- 5T7N6
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 21 E Huron St APT 807, Chicago, IL 60611, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A new and disruptive gene based therapy for atrial fibrillation | National Heart Lung and Blood Institute (NIH) | $1,412,149 | |
| A new and disruptive gene based therapy for atrial fibrillation | National Heart Lung and Blood Institute (NIH) | $4,774,483 |
Quick answers
Is Inomagen Therapeutics, Inc. registered in SAM.gov?
Yes. Inomagen Therapeutics, Inc.'s SAM.gov registration is active through April 16, 2027.
What is Inomagen Therapeutics, Inc.'s most recent federal award?
Inomagen Therapeutics, Inc.'s most recent federal grant award is A new and disruptive gene based therapy for atrial fibrillation (R44HL187127), from National Heart Lung and Blood Institute (NIH), on September 1, 2026.
On GovTribe
See Inomagen Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors